Genmab raises 2022 sales outlook to top USD 1.6bn

Genmab ended 2021 with a revenue of DKK 8.5bn (USD 1.3bn), compared to DKK 10.1bn (USD 1.5bn) in 2020, and an operating profit (EBIT) of DKK 3bn (USD 461m) against DKK 6.3bn (USD 964m) the preceding year, when an extraordinary one-off payment of DKK 4.4bn (USD 672m) from partner Abbvie lifted profits.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novartis increases sales of Genmab-developed sclerosis drug
For subscribers